… Naples, FL — Leading opponents of the biosimilars policy included in health reform … ” on
health care reform, their analysis of the biosimilars debate echoes broader concerns about how …

… [49] The legal basis for biosimilars in the EU is found in “Article 6 of … characterization methods,
the idea of an “identical copy” is not an acceptable one for pairing biologics and biosimilars…

… above, we conducted the data analysis in two stages. First, … in terms of the seven dimensions
as defined above. Such an … are diversified and developed as biosimilar to the foreign …

… or entrance of biosimilars after patent expiries. … a process analysis of the present market
authorization and reimbursement process. We complemented this with a systematic review of …

… The Donabedian model has served as a systematic, holistic guide to measuring health
care quality that encompasses three main types of quality measures: structural characteristics, …

… entities (NCEs) that were approved by the Food and Drug Administration (USA) are of
natural product origin [1], and there is a rapidly growing market for biologics and biosimilars, ie …

… in all versions of the manuscript concept and design, literature review, and interpretation of
data. Since this is a debate article, no empirical data collection and analysis was performed. …

… specific characteristics). By contrast, the commonly accepted … that is informed by a systematic
review of evidence and an … few circumstances in which two biosimilar agents are directly …

… The European Union (EU) adapted a framework for biosimilars in 2004, which paved the
way to the approval of the first biosimilar human recombinant growth hormone, Omnitrope (…

… The term ‘liquid biopsy’ is strictly referred to a blood test used for the isolation and characterization
… features, by analogy to the definition of a ‘tissue’ biopsy. From a more general point of …